The global consumer genomics market size was estimated at USD 1.26 billion in 2018 and is projected to expand at a CAGR of 20.3% from 2019 to 2025. The market is on the verge of turning into a mainstream phenomenon owing to the broadening options for the application of genetic tests. Moreover, the market is poised to be benefitted from the slow improvement in the adoption of genealogy services that assist the consumers to have an in-depth analysis of their ancestors, family tree, and risk of developing inherited health conditions.
The declining cost of sequencing has subsequently reduced the price of consumer genomic products and thus increased its accessibility to the consumer. This is due to a reduction of fixed costs and internal resource utilization by companies such as Illumina and Veritas, to deliver whole genome sequencing at low prices for the introduction of cost-effective genetic tests.
The companies are also stressing on the consumer privacy norms, the recent launch of Helix’s test that looks for two types of cancer and cholesterol, intends to maintain privacy by requesting payment and a two-way verification. In addition to this, Perkin Elmer, co-partner in the development of this test that was launched in April 2019 has focused on the interpretation of the test as an important parameter to help patients, understand the positive as well as negative outcomes.
Rising funding from market participants to support the consumer genomics-based operations boosts the demand for DTC testing solutions. For instance, in March 2018, Helix raised a funding of USD 200 million as well as partnered with fifty firms and medical centers to strengthen its online marketplace for genetic test kits.
Improvement in regulatory reforms pertaining to the marketing of DTC products is anticipated to propel the development and sales of consumer genomics products. In June 2018, the U.S. FDA removed some regulatory legislation for the marketing of consumer genomic products. Thereby, companies can commercialize their tests after obtaining a first premarket authorization without any additional review.
Continuous initiatives, such as product development and investment for portfolio expansion, are being undertaken by key players to maintain their competitive edge in the market. In March 2018, 23andMe received FDA authorization for its DTC genetic tests to test BRCA1 and BRCA2–genes that are linked with ovarian, prostate, and breast cancer.
Emerging competitors are expected to offer rigid competition to the existing participants through their various growth strategies. Market participants are increasing the advertising spend thus leading to awareness and adoption amongst the customers. Furthermore, the growing adoption of DTC tests has encouraged the market leaders to expand their genealogy research subscription business. For example, Ancestry DNA has nearly 2.5 million users globally and each customer pays an average fee of USD 20 per month to access the Ancestry’s research data and tools. Thus, a rise in sales of DNA kit results in organic revenue growth for the operating key leaders.
A substantial number of applications are linked with consumer genetic tests that are available directly to customers via the internet or physicians. These DTC genetic tests implement the raw DNA data of consumers to extract the information pertaining to paternal and maternal relatedness, ancestry, disease susceptibility, and the response of drugs on the individuals’ body.
Furthermore, there are other emerging applications of consumer genomics that include the use of genetic analysis in lifestyle, diet, and nutritional plans, sports research, noninvasive prenatal testing, carrier screening, and others. The launch of DTC tests based on such applications is anticipated to positively impact consumer genomics market growth.
New market entrants such as Pathway Genomics, Helix, and others are engaged in delivering nutrigenetic testing directly to the consumers thus contributing to the revenue growth in the lifestyle, wellness, and nutrition segment. For instance, in July 2017, DNAFit partnered with Helix to introduce its five new DNA-based products that enable the customers to have knowledge about their meal plans, nutrition supplements, and wellness plans. Such initiatives by emerging companies are anticipated to foster the growth of lifestyle, wellness, and nutrition segment.
North America held the largest market share in 2018 and will maintain its position over the forecast years. However, Asia Pacific is anticipated to be the fastest-growing regional market. Awareness programs about consumer genetic tests and developments undertaken by government bodies accelerate genetic research in Asian countries. For instance, in March 2016, the government of China launched Precision Medicine Initiative that aims at prioritizing genomic studies for better healthcare outcomes and enables precision medicine programs in the country.
A rise in the number of companies investing in emerging nations of Asia Pacific also drives the market growth in this region. Singapore seems to be a hotspot for the growth in genomics as a result of significant initiatives taken up by bioinformatics firms in this country.
Some prominent companies in this market include 23andMe, Inc.; Ancestry; Color Genomics, Inc.; Helix OpCo LLC; Gene By Gene, Ltd. (FamilyTree DNA); Mapmygenome; Positive Biosciences, Ltd.; Futura Genetics; MyHeritage Ltd.; Pathway Genomics; Xcode Life; Diagnomics, Inc.; and Toolbox Genomics.
These participants are adopting different ways to establish their market presence. Smaller companies, such as Promethease, continue to occupy a niche by analyzing genetic information and providing direct education to the public rather than choosing a geneticist in the process. On the other hand, Helix, in collaboration with Perkin Elmer, is providing a test accompanied by digital genetic counselor if required, by the virtue of digital health & genetics startup Genome Medical.
|
Attribute |
Details |
|
Base year for estimation |
2018 |
|
Actual estimates/Historical data |
2014 - 2017 |
|
Forecast period |
2019 - 2025 |
|
Market representation |
Revenue in USD Million and CAGR from 2019 to 2025 |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, and MEA |
|
Country Scope |
U.S., Canada, Germany, U.K., Japan, China, Australia, India, Singapore, Brazil, and South Africa, |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
|
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global consumer genomics market report on the basis of application and region:
Application Outlook (Revenue, USD Million, 2014 - 2025)
Genetic Relatedness
Diagnostics
Lifestyle, Wellness, & Nutrition
Ancestry
Reproductive Health
Personalized Medicine & Pharmacogenetic Testing
Sports Nutrition & Health
Others
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Australia
India
Singapore
Latin America
Brazil
Middle East and Africa (MEA)
South Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
